Skip to main content

Table 1 Socio-demographic characteristics and clinical profile of the sample ( n = 124)

From: Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample

Variables

Frequencies, means and SD

Frequencies, means and SD

(Initial sample)

(Follow up sample)

First-episode psychosis patients

Chronically ill patients

First-episode psychosis patients

Chronically ill patients

(n= 63)

(n= 61)

(n= 58)

(n= 55)

Socio-demographic data

    

 1. Age

27.03 (6.74)

44.80 (12.70)

  

 2. Sex

    

  Males

34 (54.0%)

34 (55.7%)

30 (51.7%)

30 (54.5%)

  Females

29 (46.0%)

27 (44.3%)

28 (48.3%)

25 (45.5%)

Clinical profile

    

 1. Treatment duration

23.06 (15.45) days

20.5 (12.98) years

  

 2. BPRSa

23.70 (13.00)

19.05 (8.31)

19.05 (11.00)

16.48 (9.19)

 3. GAFb

52.78 (11.72)

50.38 (12.20)

59.57 (13.38)

51.93 (12.46)

 4. BARSc

0.81 (1.79)

1.36 (2.13)

0.55 (1.52)

2.11 (2.53)

 5. SASc

0.08 (0.28)

0.25 (0.33)

0.08 (0.22)

0.46 (0.50)

 6. AIMSc

0.22 (1.31)

2.59 (5.02)

0.15 (0.77)

3.32 (5.92)

 7. Chlorpromazine equivalent dosage

387.54 (155.51)

646.81 (412.78)

315.28 (140.04)

568.73 (357.97)

 8. Body mass index

23.91 (3.83)

26.07 (4.75)

  
  1. aMeasure of the severity of psychopathology. bGlobal index of functioning. cDrug adverse effect scales.